A Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Safety and Pharmacokinetic Study of Ascending Doses of CB-183,315 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Surotomycin (Primary)
- Indications Clostridium infections; Diarrhoea
- Focus Adverse reactions
- Sponsors Cubist Pharmaceuticals
- 22 Jan 2010 Status changed from recruiting to completed, according to a Cubist Pharmacueticals media release.
- 02 Mar 2009 New trial record.